12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Actemra tocilizumab regulatory update

Chugai said Japan's Ministry of Health, Labor and Welfare approved subcutaneous Actemra tocilizumab to treat rheumatoid arthritis that does not respond sufficiently >=1 existing therapies. Last quarter, Chugai and Roche said FDA accepted for review a BLA from Roche's...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >